Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INO-4700
- Development stage
- Discontinued
- Lead developer
- Inovio Pharmaceuticals
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
INO-4700 is an investigational DNA plasmid vaccine candidate developed by Inovio Pharmaceuticals, in collaboration with GeneOne Life Science, for the prevention of Middle East Respiratory Syndrome (MERS), a respiratory disease caused by the MERS coronavirus (MERS-CoV). The vaccine is designed to deliver genetic sequences encoding the MERS-CoV spike protein into host cells, thereby inducing both humoral (antibody) and cellular (T-cell) immune responses. It is administered intradermally using Inovio's proprietary CELLECTRA electroporation device, which facilitates the entry of the DNA plasmid into cells. Although Phase 1 and Phase 1b/2a clinical trials demonstrated that the vaccine was well-tolerated and immunogenic, the development program was discontinued in November 2022 after a two-dose regimen failed to meet the specific criteria for further advancement set by the Coalition for Epidemic Preparedness Innovations (CEPI).
- Other names
- MERS-CoV DNA vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on INO-4700.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INO-4700.